Companies Announce a Collaboration for the Development of AMP-110 - An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases
New York, NY/Rockville, MD (Vocus) August 25, 2009 -- Amplimmune, Inc., a Maryland-based biotechnology company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a collaboration to support the development of Amplimmune's AMP-110 therapeutic candidate. This novel and proprietary biological molecule, or biologic, is specifically designed to target and prevent the abnormal immune responses associated with multiple sclerosis and other autoimmune diseases.
The agreement with Amplimmune is the third in a series of growing partnerships between Fast Forward and emerging biotechnology companies. "We are pleased to partner with Amplimmune to advance the development of new treatments for MS," said Dr. Timothy Coetzee, President of Fast Forward. "AMP-110 represents an important inventive approach to inhibiting inflammatory responses in multiple sclerosis." Adds Dr. Coetzee, "Modulating the immune system by using costimulatory and coinhibitory biologics is an active area of research and has significant potential in developing new therapies for MS. AMP-110 fits our profile for supporting innovative and promising new treatments for MS."
"Fast Forward's support provides a strong, independent and scientific validation for developing Amplimmune's AMP-110 for treating MS," said Mr. Michael Richman, President and CEO of Amplimmune. "Building on the exciting discovery of
Copyright©2009 Vocus, Inc.
All rights reserved